|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SLC18A2 |
Gene summary for SLC18A2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SLC18A2 | Gene ID | 6571 |
| Gene name | solute carrier family 18 member A2 | |
| Gene Alias | PKDYS2 | |
| Cytomap | 10q25.3 | |
| Gene Type | protein-coding | GO ID | GO:0001504 | UniProtAcc | Q05940 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 6571 | SLC18A2 | CA_HPV_1 | Human | Cervix | CC | 2.03e-21 | -6.02e-01 | 0.0264 |
| 6571 | SLC18A2 | CA_HPV_3 | Human | Cervix | CC | 1.46e-03 | -3.85e-01 | 0.0414 |
| 6571 | SLC18A2 | N_HPV_2 | Human | Cervix | N_HPV | 1.54e-08 | -5.13e-01 | -0.0131 |
| 6571 | SLC18A2 | CCI_1 | Human | Cervix | CC | 1.05e-04 | -7.32e-01 | 0.528 |
| 6571 | SLC18A2 | CCI_2 | Human | Cervix | CC | 1.41e-02 | -6.88e-01 | 0.5249 |
| 6571 | SLC18A2 | CCI_3 | Human | Cervix | CC | 3.17e-05 | -7.16e-01 | 0.516 |
| 6571 | SLC18A2 | CCII_1 | Human | Cervix | CC | 2.80e-08 | -7.21e-01 | 0.3249 |
| 6571 | SLC18A2 | Tumor | Human | Cervix | CC | 4.93e-29 | -7.32e-01 | 0.1241 |
| 6571 | SLC18A2 | sample1 | Human | Cervix | CC | 3.97e-08 | -7.32e-01 | 0.0959 |
| 6571 | SLC18A2 | sample3 | Human | Cervix | CC | 7.30e-28 | -7.32e-01 | 0.1387 |
| 6571 | SLC18A2 | H2 | Human | Cervix | HSIL_HPV | 3.77e-25 | -7.27e-01 | 0.0632 |
| 6571 | SLC18A2 | L1 | Human | Cervix | CC | 3.88e-11 | -7.32e-01 | 0.0802 |
| 6571 | SLC18A2 | T1 | Human | Cervix | CC | 2.47e-19 | -7.32e-01 | 0.0918 |
| 6571 | SLC18A2 | T2 | Human | Cervix | CC | 7.21e-04 | -7.32e-01 | 0.0709 |
| 6571 | SLC18A2 | T3 | Human | Cervix | CC | 4.34e-27 | -7.32e-01 | 0.1389 |
| 6571 | SLC18A2 | EOLP-1 | Human | Oral cavity | EOLP | 2.85e-13 | 5.14e-01 | -0.0202 |
| 6571 | SLC18A2 | EOLP-2 | Human | Oral cavity | EOLP | 4.55e-21 | 7.34e-01 | -0.0203 |
| 6571 | SLC18A2 | NEOLP-1 | Human | Oral cavity | NEOLP | 3.66e-03 | 3.16e-01 | -0.0194 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00512359 | Cervix | CC | maintenance of location | 78/2311 | 327/18723 | 5.18e-09 | 4.92e-07 | 78 |
| GO:00096369 | Cervix | CC | response to toxic substance | 52/2311 | 262/18723 | 3.34e-04 | 3.52e-03 | 52 |
| GO:00725939 | Cervix | CC | reactive oxygen species metabolic process | 47/2311 | 239/18723 | 7.74e-04 | 6.87e-03 | 47 |
| GO:00097915 | Cervix | CC | post-embryonic development | 20/2311 | 80/18723 | 1.40e-03 | 1.10e-02 | 20 |
| GO:20003779 | Cervix | CC | regulation of reactive oxygen species metabolic process | 32/2311 | 157/18723 | 2.78e-03 | 1.87e-02 | 32 |
| GO:00019752 | Cervix | CC | response to amphetamine | 10/2311 | 33/18723 | 5.07e-03 | 3.00e-02 | 10 |
| GO:00140754 | Cervix | CC | response to amine | 13/2311 | 49/18723 | 5.34e-03 | 3.10e-02 | 13 |
| GO:19034095 | Cervix | CC | reactive oxygen species biosynthetic process | 15/2311 | 64/18723 | 9.89e-03 | 4.85e-02 | 15 |
| GO:000963614 | Cervix | HSIL_HPV | response to toxic substance | 24/737 | 262/18723 | 1.14e-04 | 2.36e-03 | 24 |
| GO:005123514 | Cervix | HSIL_HPV | maintenance of location | 26/737 | 327/18723 | 5.67e-04 | 8.04e-03 | 26 |
| GO:001407511 | Cervix | HSIL_HPV | response to amine | 8/737 | 49/18723 | 5.99e-04 | 8.37e-03 | 8 |
| GO:190340911 | Cervix | HSIL_HPV | reactive oxygen species biosynthetic process | 9/737 | 64/18723 | 8.56e-04 | 1.10e-02 | 9 |
| GO:200037714 | Cervix | HSIL_HPV | regulation of reactive oxygen species metabolic process | 15/737 | 157/18723 | 1.37e-03 | 1.56e-02 | 15 |
| GO:00019751 | Cervix | HSIL_HPV | response to amphetamine | 6/737 | 33/18723 | 1.63e-03 | 1.77e-02 | 6 |
| GO:007259314 | Cervix | HSIL_HPV | reactive oxygen species metabolic process | 19/737 | 239/18723 | 2.99e-03 | 2.76e-02 | 19 |
| GO:19034263 | Cervix | HSIL_HPV | regulation of reactive oxygen species biosynthetic process | 7/737 | 52/18723 | 4.07e-03 | 3.49e-02 | 7 |
| GO:005123524 | Cervix | N_HPV | maintenance of location | 33/534 | 327/18723 | 3.40e-10 | 2.21e-07 | 33 |
| GO:000963624 | Cervix | N_HPV | response to toxic substance | 27/534 | 262/18723 | 9.00e-09 | 1.71e-06 | 27 |
| GO:200037724 | Cervix | N_HPV | regulation of reactive oxygen species metabolic process | 12/534 | 157/18723 | 1.85e-03 | 1.83e-02 | 12 |
| GO:1903427 | Cervix | N_HPV | negative regulation of reactive oxygen species biosynthetic process | 4/534 | 21/18723 | 2.66e-03 | 2.35e-02 | 4 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0501220 | Cervix | CC | Parkinson disease | 102/1267 | 266/8465 | 1.81e-21 | 1.47e-19 | 8.66e-20 | 102 |
| hsa05012110 | Cervix | CC | Parkinson disease | 102/1267 | 266/8465 | 1.81e-21 | 1.47e-19 | 8.66e-20 | 102 |
| hsa0501225 | Cervix | HSIL_HPV | Parkinson disease | 43/459 | 266/8465 | 6.69e-11 | 6.53e-09 | 5.28e-09 | 43 |
| hsa0501235 | Cervix | HSIL_HPV | Parkinson disease | 43/459 | 266/8465 | 6.69e-11 | 6.53e-09 | 5.28e-09 | 43 |
| hsa0501244 | Cervix | N_HPV | Parkinson disease | 45/349 | 266/8465 | 1.93e-16 | 1.75e-14 | 1.37e-14 | 45 |
| hsa0501254 | Cervix | N_HPV | Parkinson disease | 45/349 | 266/8465 | 1.93e-16 | 1.75e-14 | 1.37e-14 | 45 |
| hsa0501245 | Oral cavity | EOLP | Parkinson disease | 75/1218 | 266/8465 | 2.26e-09 | 5.62e-08 | 3.32e-08 | 75 |
| hsa0472812 | Oral cavity | EOLP | Dopaminergic synapse | 33/1218 | 132/8465 | 8.18e-04 | 3.04e-03 | 1.79e-03 | 33 |
| hsa0501255 | Oral cavity | EOLP | Parkinson disease | 75/1218 | 266/8465 | 2.26e-09 | 5.62e-08 | 3.32e-08 | 75 |
| hsa0472813 | Oral cavity | EOLP | Dopaminergic synapse | 33/1218 | 132/8465 | 8.18e-04 | 3.04e-03 | 1.79e-03 | 33 |
| hsa0501262 | Oral cavity | NEOLP | Parkinson disease | 78/1112 | 266/8465 | 1.34e-12 | 1.06e-10 | 6.68e-11 | 78 |
| hsa0472821 | Oral cavity | NEOLP | Dopaminergic synapse | 30/1112 | 132/8465 | 1.61e-03 | 7.30e-03 | 4.59e-03 | 30 |
| hsa0501272 | Oral cavity | NEOLP | Parkinson disease | 78/1112 | 266/8465 | 1.34e-12 | 1.06e-10 | 6.68e-11 | 78 |
| hsa0472831 | Oral cavity | NEOLP | Dopaminergic synapse | 30/1112 | 132/8465 | 1.61e-03 | 7.30e-03 | 4.59e-03 | 30 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SLC18A2 | SNV | Missense_Mutation | novel | c.340N>A | p.Pro114Thr | p.P114T | Q05940 | protein_coding | tolerated(0.26) | benign(0.062) | TCGA-3C-AALK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD |
| SLC18A2 | SNV | Missense_Mutation | c.475N>A | p.Pro159Thr | p.P159T | Q05940 | protein_coding | tolerated(0.57) | benign(0.015) | TCGA-A8-A09E-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | anastrozole | SD | |
| SLC18A2 | insertion | In_Frame_Ins | novel | c.284_285insGTTCTCAGGGCCGTTGGGGGCATGGTTCTTTCTAGTGAG | p.Asp95delinsGluPheSerGlyProLeuGlyAlaTrpPhePheLeuValSer | p.D95delinsEFSGPLGAWFFLVS | Q05940 | protein_coding | TCGA-A2-A0T2-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | xeloda | PD | ||
| SLC18A2 | insertion | Nonsense_Mutation | novel | c.359_360insTAAGTAAAGTG | p.Glu120AspfsTer3 | p.E120Dfs*3 | Q05940 | protein_coding | TCGA-AN-A0FD-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| SLC18A2 | SNV | Missense_Mutation | c.1369N>A | p.Gly457Arg | p.G457R | Q05940 | protein_coding | deleterious(0) | probably_damaging(0.988) | TCGA-C5-A1MJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| SLC18A2 | SNV | Missense_Mutation | novel | c.1340N>A | p.Ile447Asn | p.I447N | Q05940 | protein_coding | deleterious(0) | possibly_damaging(0.853) | TCGA-C5-A8XI-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | SD |
| SLC18A2 | SNV | Missense_Mutation | novel | c.892N>A | p.Ala298Thr | p.A298T | Q05940 | protein_coding | deleterious(0.01) | probably_damaging(0.964) | TCGA-EA-A3HU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| SLC18A2 | SNV | Missense_Mutation | novel | c.165N>C | p.Lys55Asn | p.K55N | Q05940 | protein_coding | tolerated(0.5) | benign(0.003) | TCGA-VS-A9V1-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
| SLC18A2 | SNV | Missense_Mutation | c.815C>A | p.Pro272Gln | p.P272Q | Q05940 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AA-3818-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| SLC18A2 | SNV | Missense_Mutation | c.213N>G | p.Ile71Met | p.I71M | Q05940 | protein_coding | tolerated(0.23) | benign(0.018) | TCGA-AA-3851-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 6571 | SLC18A2 | DRUGGABLE GENOME, TRANSPORTER | inhibitor | CHEMBL1201178 | LISDEXAMFETAMINE DIMESYLATE | |
| 6571 | SLC18A2 | DRUGGABLE GENOME, TRANSPORTER | Lobeline | LOBELINE | ||
| 6571 | SLC18A2 | DRUGGABLE GENOME, TRANSPORTER | inhibitor | 178101473 | ||
| 6571 | SLC18A2 | DRUGGABLE GENOME, TRANSPORTER | Alkavervir | ALKAVERVIR | ||
| 6571 | SLC18A2 | DRUGGABLE GENOME, TRANSPORTER | inhibitor | 178101328 | ||
| 6571 | SLC18A2 | DRUGGABLE GENOME, TRANSPORTER | bupropion | BUPROPION | 22947179 | |
| 6571 | SLC18A2 | DRUGGABLE GENOME, TRANSPORTER | NBI-98854 | VALBENAZINE TOSYLATE | ||
| 6571 | SLC18A2 | DRUGGABLE GENOME, TRANSPORTER | inhibitor | CHEMBL2364639 | VALBENAZINE | |
| 6571 | SLC18A2 | DRUGGABLE GENOME, TRANSPORTER | AV 133 | |||
| 6571 | SLC18A2 | DRUGGABLE GENOME, TRANSPORTER | DEXTROAMPHETAMINE | DEXTROAMPHETAMINE |
| Page: 1 2 3 4 5 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |